2. Epigenetics Cell Cycle/DNA Damage Apoptosis
  3. HDAC CDK Apoptosis
  4. CDK/HDAC-IN-2

CDK/HDAC-IN-2 is a potent HDAC/CDK dual inhibitor with IC50 of 6.4, 0.25, 45, >1000, 8.63, 0.30, >1000 nM for HDAC1, HDAC2, HDAC3, HDAC6,8, CDK1, CDK2, CDK4,6,7, respectively. CDK/HDAC-IN-2 shows excellent antiproliferative activities. CDK/HDAC-IN-2 induces apoptosis and cell cycle arrest at G2/M phase. CDK/HDAC-IN-2 shows potent antitumor efficacy.

For research use only. We do not sell to patients.

CDK/HDAC-IN-2 Chemical Structure

CDK/HDAC-IN-2 Chemical Structure

CAS No. : 2580938-58-3

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

CDK/HDAC-IN-2 Related Antibodies

Top Publications Citing Use of Products

View All HDAC Isoform Specific Products:

View All Isoforms

View All CDK Isoform Specific Products:

View All Isoforms

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

CDK/HDAC-IN-2 is a potent HDAC/CDK dual inhibitor with IC50 of 6.4, 0.25, 45, >1000, 8.63, 0.30, >1000 nM for HDAC1, HDAC2, HDAC3, HDAC6,8, CDK1, CDK2, CDK4,6,7, respectively. CDK/HDAC-IN-2 shows excellent antiproliferative activities. CDK/HDAC-IN-2 induces apoptosis and cell cycle arrest at G2/M phase. CDK/HDAC-IN-2 shows potent antitumor efficacy[1].

IC50 & Target[1]

HDAC1

6.4 nM (IC50)

HDAC2

0.25 nM (IC50)

HDAC3

45 nM (IC50)

HDAC6

>1000 nM (IC50)

HDAC8

>1000 nM (IC50)

CDK1

8.63 nM (IC50)

CDK2

0.30 μM (IC50)

CDK4

>1000 nM (IC50)

CDK6

>1000 nM (IC50)

CDK7

>1000 nM (IC50)

In Vitro

CDK/HDAC-IN-2 (compound 7c) shows antiproliferative activity with IC50s of 0.71, 1.20, 1.83, 4.19, 7.76, 4.47 µM for HCT116, A375, Hela, H460, SMMC7721, NIH 3T3 cells, respectively[1].
CDK/HDAC-IN-2 (24 h) shows anti-migration ability in A375 and H460 cells[1].
CDK/HDAC-IN-2 (0.5, 1, 2 µM) induces apoptosis and cell cycle arrest at G2/M phase[1].
CDK/HDAC-IN-2 accelerates intracellular ROS accumulation, leading to cancer cell death[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CDK/HDAC-IN-2 Related Antibodies

Cell Cycle Analysis[1]

Cell Line: A375, HCT116, H460, Hela cells
Concentration: 0.5, 1, 2 µM
Incubation Time: 24 h
Result: Induced cell cycle arrest at G2/M phase.

Apoptosis Analysis[1]

Cell Line: A375, HCT116, H460, Hela cells
Concentration: 0.5, 1, 2 µM
Incubation Time: 48 h
Result: Induced cell apoptosis with the apoptosis rates of A375, HCT116 cells of 97.22%, 60.6%, respectively.
In Vivo

CDK/HDAC-IN-2 (12.5, 25 mg/kg; IP; once daily for 21 days) shows antitumor efficacy in the HCT116 xenograft model (TGI= 51.0%)[1].
Pharmacokinetic Parameters of CDK/HDAC-IN-2 in ICR male mice[1].

compound 7c
Dose (mg/kg) 20
administration i.p.
t1/2 (h) 2.61
Tmax (h) 2.00
Cmax (h) 7570
AUC0-∞ (ng h/mL) 30700
MRT0-∞ (ng h/mL) 3.31
F (%) 63.6
ICR male mice; 20 mg/kg, i.p.[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: ICR male mice[1]
Dosage: 20 mg/kg
Administration: IP
Result: Showed good Pharmacokinetic parameters with bioavailability of F= 63.6%.
Animal Model: 5-6 weeks, BALB/c female mice (HCT116 xenograft nude mice models)[1]
Dosage: 12.5, 25 mg/kg
Administration: IP, once daily for 21 days
Result: Effectively inhibited the growth of HCT116 xenograft tumors tumor growth inhibitions (TGI) at 12.5 and 25 mg/kg of 37.0% and 51.0%, respectively.
Molecular Weight

523.37

Formula

C25H20Cl2N6O3
CAS No.
SMILES

NC1=CC=CC=C1NC(C2=CC=C(C=C2)CNC(C3=NNC=C3NC(C4=C(C=CC=C4Cl)Cl)=O)=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

CDK/HDAC-IN-2 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

CDK/HDAC-IN-22580938-58-3HDACCDKApoptosisHistone deacetylasesCyclin dependent kinaseantiproliferativeantitumorG2/M phaseapoptosisHCT116 xenograft modelA375HCT116H460Hela cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
CDK/HDAC-IN-2
Cat. No.:
HY-146276
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.